Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice [Corrigendum]
Niu S, Ren Q, Chen S, et al. Diabetes Metab Syndr Obes. 2023;16:2549–2560. The authors have advised the correspondence section on page 2549 is incorrect. The correct correspondence details are as follows. Correspondence: Shuchun Chen, Department of Endocrinology, Hebei General Hospital, S...
Main Authors: | Niu S, Ren Q, Chen S, Pan X, Yue L, Chen X, Li Z, Zhen R |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2023-09-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Subjects: | |
Online Access: | https://www.dovepress.com/corrigendum-metabolic-and-hepatic-effects-of-empagliflozin-on-nonalcoh-peer-reviewed-fulltext-article-DMSO |
Similar Items
-
Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice
by: Niu S, et al.
Published: (2023-08-01) -
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
by: Yuyuan Zhang, et al.
Published: (2022-02-01) -
Transcriptomic Analysis Reveals the Protective Effects of Empagliflozin on Lipid Metabolism in Nonalcoholic Fatty Liver Disease
by: Yuting Ma, et al.
Published: (2021-12-01) -
The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile
by: Alana Aragón-Herrera, et al.
Published: (2022-02-01) -
Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice
by: Yang Y, et al.
Published: (2024-03-01)